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OBJECTIVE — To study trough levels of metformin in serum and its intra-individual varia-
tion in patients using a newly developed assay.
RESEARCH DESIGN AND METHODS — Trough serum levels of metformin were
measuredonceusingliquidchromatography–tandemmassspectrometry(LCMSMS)in137type
2 diabetic patients with varying renal function (99 men) and followed repeatedly during 2
months in 20 patients (16 men) with estimated glomerular ﬁltration rate (eGFR) 60 ml/min/
1.73 m
2 body surface.
RESULTS — Patients with eGFR 60, 30–60, and 30 ml/min/1.73 m
2 had median trough
metformin concentrations of 4.5 mol/l (range 0.1–20.7, n  107), 7.71 mol/l (0.12–15.15,
n21),and8.88mol/l(5.99–18.60,n9),respectively.Themedianintra-individualoverall
coefﬁcient of variation was 29.4% (range 9.8–74.2).
CONCLUSIONS — Determination of serum metformin with the LCMSMS technique is
useful in patients on metformin treatment. Few patients had values 20 mol/l. Metformin
measurement is less suitable for dose titration.
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M
etformin is an insulin sensitizer
used for treating type 2 diabetes,
and the treatment is only rarely
complicated by lactic acidosis. The sub-
stance is cleared from the blood through
the kidneys (1), and impaired renal func-
tion may lead to accumulation.
Wehavecombinednewtechnologies:
liquid chromatography–tandem mass
spectrometry(LCMSMS)andhydrophilic
interaction liquid chromatography (2) in
the development of a novel method for
determination of metformin in serum.
Theaimwastostudytroughlevelsofmet-
formin in type 2 diabetic patients and to
assess intra-individual variations in pa-
tients with renal impairment.
RESEARCH DESIGN AND
METHODS— Fasting venous blood
samples were obtained in 137 type 2
diabetic patients (99 men, median age
60 years [range 31–83]), and 20 pa-
tients with glomerular ﬁltration rate
(GFR) 60 ml/min/1.73 m
2 (16 men,
median age 68 years [range 48–83])
were studied at weeks 0, 2, 4, and 8.
Serum metformin, cystatin C, and cre-
atinine were analyzed in both groups.
Allparticipantsprovidedinformedcon-
sent, and the study was approved by the
local ethics committee.
Method for analysis of metformin
One part serum was mixed with 10 parts
internal standard fortiﬁed acetonitril. Af-
ter centrifugation, one part of the super-
natant was diluted with 20 parts of the
mobile phase. Then 5 l of the diluted
supernatant was injected into the liquid
chromatograph.
The mobile phase is a mixture of
water, acetonitril, formic acid, and am-
monium acetate (pH 2–3). It elutes fen-
formin and metformin after 2 and 3
min, respectively, from the HILIC col-
umn (Merck SeQuant, Umea, Sweden).
The mobile phase enters the mass spec-
trometer, and positively ionized mole-
cules of the eluted compounds are
formed by electro spray ionization (3).
The positively ionized molecules are
fragmented by collision with nitrogen
(3) to form fragments with the mass/
charge of 70.8 and 105.2 for metformin
and fenformin, respectively. The inten-
sity of these fragments are measured
and calculated to represent concentra-
tion data of metformin.
We used a standard high-perfor-
mance liquid chromatograph combined
with a triple quadruple mass spectrome-
ter (Sciex API 4000; Applied Biosystems,
Carlsbad,CA).Thechromatographicsep-
arationofmetforminanditsinternalstan-
dard fenformin was performed with
isocratic HILIC elution.
1,1-Dimethylbiguanide hydrochloride
and fenformin hydrochloride (Sigma-
Aldrich, St. Louis, MO) were used as a ref-
erence substance for metformin and
internal standard in the assay, respectively.
The lower threshold for detection is
0.05 mol/l, and the results are linear be-
tween 0.05 and 125 mol/l. At concen-
trations 125 mol/l the sample is
diluted. Coefﬁcient of variation (CV) per-
centage during 20 months is 12% at the
3.6 mol/l level and 6.3% at the 33
mol/l level, with 56 samples at each
level.
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Estimation of GFR was based on cystatin
C (4–6) determined by an immunoturbi-
dimetric method on a Hitachi Modular P
analysis system. Use of creatinine for esti-
mating GFR did not change the results of
the study (data not shown).
Statistical analysis
Results are given as median values and
range or interquartile range. SPSS 15.0
wasused.Wilcoxonrank-sum(P0.05)
and Spearman nonparametric tests (P 
0.05) were used when appropriate.
RESULTS
Trough levels in relation to renal
function
Of the 137 patients, 9 had an eGFR 30
ml/min/1.73 m
2 and a median trough
value of S-metformin at 8.88 mol/l
(range 5.99–18.60); 21 patients had an
eGFR of 30–60 ml/min/1.73 m
2 and a
median S-metformin of 7.71 mol/l
(range0.12–15.15);and107patientshad
an eGFR of 60 ml/min/1.73m
2 and a
medianS-metforminof4.5mol/l(range
0.1–20.7). The median doses of met-
formin were 1,500 mg (1,000–3,000),
1,500 mg (500–3,000), and 1,500 mg
(500–3,000) for each group, respectively
(Fig. 1).
Intra-individual variance of
metformin concentrations
The median intra-individual variation of
the S-metformin level in the 20 patients
during the 8-week period with repeated
measurementswasCV29.4%(range9.8–
74.2). Of the 20 patients, 6 had an eGFR
30 ml/min/1.73 m
2, and 14 had an
eGFR 30–63 ml/min/1.73 m
2. Median S-
metformin was 10 mol/l (interquartile
range 5.3–16). There was no correlation
betweenCVofS-metforminandGFR(r
0.3131, P  0.156).
The CV of the four eGFR values was
7.5% (range 5.9–12.5). Median eGFR at
weeks 0, 2, 4, and 8 was 37, 34, 36, and
33, respectively. There was a signiﬁcant
difference between the ﬁrst (week 0) and
last (week 8) median value of eGFR (P 
0.023).
CONCLUSIONS —I ti sw i d e l ya c -
knowledged that metformin therapy is
beneﬁcial in treating type 2 diabetes and
should be made available to as many pa-
tients as possible. One obstacle to this has
been the possible risk of lactic acidosis in
patientswithimpairedrenalfunction.We
have had seven cases of patients on treat-
mentwithmetforminadmittedwithlactic
acidosis with metformin levels ranging
from 256 to 682 mol/l (median 330).
These data suggest that high levels of se-
Figure 1—Box-plot of trough metformin levels in 137 patients grouped in patients with eGFR 30 ml/min/1.73 m
2 (n  9), 30–60 ml/min/1.73
m
2, and 60 ml/min/1.73 m
2 (n  107). The outliers marked in the group with eGFR 60 ml/min/1.73 m
2 are most likely due to patients
accidentally taking their medication before the blood test.
Serum metformin levels in impaired renal function
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acidosis.
Prevailingclinicalexperiencehasledto
recommendations that metformin may be
used at eGFR above 30 ml/min/1.73 m
2
(7,8). Our study supports these guidelines
showing that patients above this GFR limit
rarely had metformin levels above 20
mol/l, which seems to be a safe level.
If the current guidelines gain general
recognition it becomes even more impor-
tant to advocate cessation of metformin
therapy when renal failure develops
abruptlyorinouropinionwithanysevere
disease, especially when there is risk of
dehydration.
Results from this study show a con-
siderable intra-individual CV of 29.4%
for metformin concentrations in 20 pa-
tients with impaired renal function.
There was a wide range (10–74%) of
variability, with only four participants hav-
ing CVs below 20%. This variability proba-
bly reﬂects the heterogeneity of the study
population. The wide intra-individual vari-
ation seen in this study probably also exists
in daily clinical practice.
Based on these ﬁndings we propose
that:
● eGFR should be used to estimate renal
function in patients using metformin.
● LCMSMS can be used as a routine
method to evaluate trough serum con-
centrations of metformin and that 20
mol/l may be used as preliminary up-
per therapeutic limit.
● when intra-individual CV is high, the
technique is less suitable for dose
titration.
● LCMSMS may help to differ between
metformin-associated lactic acidosis
and other causes.
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